Volume 65, Issue 5, Pages (May 2014)

Slides:



Advertisements
Similar presentations
Volume 53, Issue 3, Pages (March 2008)
Advertisements

Volume 55, Issue 1, Pages 1-8 (January 2009)
Volume 71, Issue 2, Pages (February 2017)
The PSA Era is not Over for Prostate Cancer
Volume 59, Issue 2, Pages (February 2011)
Volume 51, Issue 2, Pages (February 2007)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 44, Issue 6, Pages (December 2003)
Volume 58, Issue 4, Pages (October 2010)
Testosterone Therapy in Men With Prostate Cancer
Volume 68, Issue 6, Pages e129-e131 (December 2015)
Volume 191, Issue 6, Pages (June 2014)
Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer  Marisa Warmuth,
Volume 74, Issue 4, Pages (October 2018)
Prostate Cancer: Highlights from 2006
Volume 69, Issue 2, Pages (February 2016)
Volume 60, Issue 5, Pages (November 2011)
Volume 53, Issue 5, Pages (May 2008)
Control of Prostate Cancer by Transrectal HIFU in 227 Patients
Volume 69, Issue 1, Pages (January 2016)
Volume 71, Issue 2, Pages (February 2017)
Prostate Cancer Epidemic in Sight?
Volume 52, Issue 4, Pages (October 2007)
Volume 72, Issue 5, Pages (November 2017)
Volume 62, Issue 6, Pages (December 2012)
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka 
Prostate Cancer Detection: A View of the Future
Volume 67, Issue 3, Pages (March 2015)
Volume 70, Issue 4, Pages (October 2016)
Low-risk Prostate Cancer: Identification, Management, and Outcomes
Volume 67, Issue 6, Pages (June 2015)
Volume 71, Issue 5, Pages (May 2017)
Laurent Boccon-Gibod  European Urology Supplements 
Volume 64, Issue 6, Pages (December 2013)
Prostate Cancer Epidemic in Sight?
The PSA Era is not Over for Prostate Cancer
Volume 61, Issue 6, Pages (June 2012)
Volume 74, Issue 3, Pages (September 2018)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 58, Issue 4, Pages (October 2010)
Volume 53, Issue 6, Pages (June 2008)
Volume 61, Issue 2, Pages (February 2012)
Volume 66, Issue 2, Pages (August 2014)
Volume 58, Issue 1, Pages 1-7 (July 2010)
Volume 63, Issue 3, Pages (March 2013)
Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia
Volume 71, Issue 1, Pages (January 2017)
Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study  Stephen H. Culp, Paul.
Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial
Volume 50, Issue 5, Pages (November 2006)
Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G
CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System
Volume 55, Issue 3, Pages (March 2009)
Volume 50, Issue 2, Pages (August 2006)
Volume 51, Issue 2, Pages (February 2007)
Volume 71, Issue 5, Pages (May 2017)
Volume 53, Issue 1, Pages (January 2008)
Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy  Matthew Mossanen, Kenneth.
The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.
European Urology is “Your” Journal
Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.
Georges-Pascal Haber, Sebastien Crouzet, Inderbir S. Gill 
Arlene Chan, Marc Buyse, Bin Yao  The Lancet Oncology 
Volume 53, Issue 6, Pages (June 2008)
Volume 51, Issue 2, Pages (February 2007)
Oncoforum Urology: Prostate Cancer 2008 at a Glance
Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas 
Volume 54, Issue 1, Pages (July 2008)
Volume 51, Issue 5, Pages (May 2007)
Presentation transcript:

Volume 65, Issue 5, Pages 907-914 (May 2014) Whole-gland Ablation of Localized Prostate Cancer with High-intensity Focused Ultrasound: Oncologic Outcomes and Morbidity in 1002 Patients  Sebastien Crouzet, Jean Yves Chapelon, Olivier Rouvière, Florence Mege-Lechevallier, Marc Colombel, Hélène Tonoli-Catez, Xavier Martin, Albert Gelet  European Urology  Volume 65, Issue 5, Pages 907-914 (May 2014) DOI: 10.1016/j.eururo.2013.04.039 Copyright © 2013 European Association of Urology Terms and Conditions

Fig. 1 Influence of pre–high-intensity focused ultrasound (HIFU) risk group on biochemical-free survival rates (Phoenix criteria) following HIFU therapy. European Urology 2014 65, 907-914DOI: (10.1016/j.eururo.2013.04.039) Copyright © 2013 European Association of Urology Terms and Conditions

Fig. 2 Overall, prostate cancer (PCa)–specific, and metastasis-free survival rates following high-intensity focused ultrasound (HIFU) treatment. European Urology 2014 65, 907-914DOI: (10.1016/j.eururo.2013.04.039) Copyright © 2013 European Association of Urology Terms and Conditions

Fig. 3 Influence of pre–high-intensity focused ultrasound (HIFU) risk group on prostate cancer–specific survival in patients treated following HIFU. European Urology 2014 65, 907-914DOI: (10.1016/j.eururo.2013.04.039) Copyright © 2013 European Association of Urology Terms and Conditions

Fig. 4 Influence of pre–high-intensity focused ultrasound (HIFU) risk group on palliative treatment–free survival following HIFU. European Urology 2014 65, 907-914DOI: (10.1016/j.eururo.2013.04.039) Copyright © 2013 European Association of Urology Terms and Conditions